You can explain all you want but the FACTS show that a person on the 4 patient study died. We don't know the exact reason but we do know they received LL.
And now we get to the heart of the EIND/Anecdotal evidence fallacy:
This was not a study this were patients of dr Agresti given EIND , they were dying patients and most survived,'Dr Agresti was very impressed how leronlimab was working. If you looking on this patients our first 11 patients in Montafiore , Dr Harish patients , from 11 only 4 survived and this was a miracle..
Maybe it was just that. 4 lucky people who survived by coincidence. Because in a larger trial those numbers did not scale. We also don't know how long all those patients were in the hospital and on the drug for. We just have the end result making it seem like there was a 36% survival rate versus the 30% survival rate in a clinical study.
What if those 4 were on the drug for 2 weeks and were out of the hospital? Well then the survival rate at day 28 becomes very, very important. Because the patients in the clinical trial were not over their COVID in just 2 weeks.